Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_assertion type Assertion NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_head.
- NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_assertion wasGeneratedBy ECO_0000203 NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_provenance.
- NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_assertion wasDerivedFrom befree-2016 NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_provenance.
- NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_assertion SIO_000772 11522269 NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_provenance.
- NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_assertion evidence source_evidence_literature NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_provenance.
- NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_assertion description "[New or potentially new markers for breast cancer include BRCA1 and BRCA2 for selecting patients at high risk of developing breast cancer, urokinase plasminogen activator and PA1-1 for assessing prognosis and HER-2 for predicting response to the therapeutic antibody, Herceptin.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP328168.RAvvg2cBF1DoUNYanpNI8EJ6WywJQdXTPDzxvchgsxifg130_provenance.